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ABSTRACT 
The use of Rho Kinase (ROCK) inhibitors as therapeutic agents in ophthalmology has been a topic of discussion for several 
years, particularly in the realm of glaucoma, Fuchs’ endothelial dystrophy, and diabetic retinopathy. In this review, the 
authors provide a detailed and comprehensive overview of the published literature on the use of Rho kinase inhibitors 
for the aforementioned purposes. A thorough search of several databases was conducted to find sufficient literature on 
ROCK inhibitors. This research found strong evidence demonstrating that inhibition of Rho kinase significantly decreases 
IOP, increases healing of the corneal endothelium, and decreases progression of diabetic retinopathy. The main side 
effect of ROCK inhibitors is conjunctival hyperemia that is often present in more than half of the patients in certain 
formulations. Additional clinical trials investigating the reviewed treatment options of Rho kinase inhibitors are 
necessary to further validate previous findings on the topic. Nonetheless, it is clear that Rho kinase inhibitors have the 
potential to be another potent therapeutic option for several chronic diseases in ophthalmology. 
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INTRODUCTION
Function of Rho kinase 
Rho  kinase is a serine/threonine protein kinase involved 
in the regulation and modulation of cell shape and size 
via action on the cytoskeleton [1]. As downstream 
effectors of Rho GTPase, Rho kinases are involved in 
calcium-independent regulation of smooth muscle 
contraction [2]. Furthermore, they have been linked with 
the control of cytoskeletal dynamics, actomyosin 
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contractile forces, cell adhesion, cell stiffening, 
extracellular matrix reorganization, and cell morphology 
[3]. These factors have been shown to be determinants 
of Aqueous Humor (AH) outflow via the trabecular 
pathway, which consists of Schlemm’s canal, trabecular 
meshwork, and juxtacanalicular tissue [4, 5]. Therefore, 
through physiological evidence, a direct relationship is 
suggested between Rho kinase functionality and AH 
outflow passing through the trabecular pathway. 
History of Rho kinase Inhibitors 
As knowledge has been obtained regarding Rho kinases, 
the relationship between this enzyme and certain 
physiological problems has come to light. Research on 
Rho kinase began in the late 1990’s and has continued to 
the present time [1, 4, 6, 7]. The majority of research has 
emphasized on Intraocular Pressure (IOP) lowering the 
effect of Rho Kinase (ROCK) inhibitors. Fewer studies 
have dealt with the restorative effect a Rho kinase 
inhibitor has on diabetic retinopathy and the healing 
effects on the corneal endothelium. At present, further 
research is being conducted on different treatment 
options, dosages, and formulas for Rho kinase inhibitors 
in ophthalmology. In 1998, Alan Hall elucidated the 
relationship between the Rho pathway and actin 
cytoskeleton functions. He showed that the Rho kinase 
pathway was an important regulator of the actin 
cytoskeleton and that various reactions within the 
pathway, coordinated with many cellular responses and 
changed different characteristics, such as shape and 
adhesion.
1
 In 2001, studies began at both the University 
of Tokyo in Japan and Duke University in North Carolina 
to investigate the effects of Rho kinase inhibitors on 
lowering of IOP [8, 9]. They were designed to discover 
how AH outflow facility was increased by the ROCK 
inhibitors.  The studies showed that, by inhibiting the 
Rho pathway, cells in the trabecular meshwork would 
alter in ways that allowed for increased outflow of AH. In 
the late 2000’s, studies commenced to determine if 
ROCK inhibitors could be used as treatment for 
glaucoma. Many of these studies were pioneered by the 
same people, who had investigated the IOP-lowering 
effects of Rho kinase inhibitors, namely Rao, Epstein, 
Vasantha, Honjo, and Tanihara, along with other 
collaborators [2, 9, 10]. 
After this period of discovery, others began research on 
the use of Rho kinase inhibitors as treatments for other 
ophthalmologic diseases.  From 2010 to the present 
time, studies have been done to investigate the further 
use of Rho kinase inhibitors for different conditions, such 
as diabetic retinopathy and corneal endothelial damage 
[11]. As knowledge was gained from these investigations, 
further clinical trials have been performed to determine 
the correct formula, dosage, and duration of use of Rho 
kinase inhibitors [11-15]. In 2014, ripasudil, a ROCK 
inhibitor, gained approval in Japan to be specifically used 
for treatment of ocular hypertension and glaucoma [5, 
16-18]. As recently as December 18th, 2017, Rhopressa, a 
Rho kinase inhibiting drug consisting of Netarsudil, 
gained Food and Drug Administration (FDA) approval; the 
first of its kind to do so in the United States of America 
[19]. 
Rho kinase Signaling Pathway 
Rho kinase is a downstream effector of the RhoA protein, 
a small GTPase.  GTPases alternate between two 
conformations: a Guanosine Triphosphate (GTP)-bound 
active conformation and a Guanosine Diphosphate 
(GDP)-bound inactive conformation.  This GTPase 
activation regulation is controlled by Guanine nucleotide 
Exchange Factors (GEFs), GTPase Activating Proteins 
(GAPs), and Guanine nucleotide Dissociation Inhibitors 
(GDIs) [2, 3, 5, 7, 20]. After activation of RhoA, the coiled-
tail serine/threonine kinase, the downstream effector 
Rho kinase, becomes active.  The Rho kinase has two 
isoforms, ROCK1 (ROK) and ROCK 2 (ROK).  Although 
both isoforms share similar effects, they also fulfill some 
isoform-specific roles. Rho kinase phosphorylates various 
intracellular substrates, including the two seen in Figure 
1, the myosin light chain, and the LIM kinase [3]. 
These substrates then interact to control actomyosin 
contractility, membrane permeability, cellular adhesion, 
cell stiffening, cell morphological changes, extracellular 
matrix organization, as well as DNA synthesis [1, 2, 10, 21]. 
As mentioned previously, these cellular characteristics 
take on a critical part in AH outflow.  Therefore, the Rho 
kinase has a direct role in affecting AH outflow. 
Application of Rho Kinase Inhibitors in Ophthalmology  
Glaucoma 
Glaucoma is classified as a progressive form of optic 
neuropathy.  There are two principal forms of glaucoma, 
including open angle and closed angle [4, 19]. The most 
predominant risk factor with either type is elevated IOP. 
In open angle glaucoma, it is proposed that this elevation 
in IOP is due to the clogging of AH drainage canal, 
through the Trabecular Meshwork (TM) [5]. Although the 
physiological mechanism for this impairment is not 
entirely known, it is proposed that the best therapeutic 
remedy for open angle glaucoma is lowering the IOP by 
enhancing the outflow of AH, as shown in Figure 2. Rho 
kinase inhibitors have been tested and proven to alter 
cell shape in the trabecular meshwork, allowing for 
enhanced AH outflow and the lowering of IOP [8, 10, 22, 
23]. 
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Figure 1: A Simplified View of Rho Kinase Involved Metabolic Pathway. 
RhoGEF: Rho Guanine nucleotide Exchange Factor; GAP: GTPase Activating Proteins; GDI: Guanine nucleotide Disassociation Inhibitor; RhoA: Ras 
Homolog Gene Family Member A; ECM: Extracellular Matrix; GTPase: Guanosine triphosphatase 
 
 
Figure 2: Simplified View of the Treatment of Glaucoma using ROCK Inhibitor Drops 
TM: Trabecular Meshwork; IOP: Intraocular Pressure; ROCK inhibitor: Rho kinase inhibitor; AH: Aqueous Humor. 
 
Corneal Endothelium 
The most internal layer of the cornea is the corneal 
endothelium, which controls corneal hydration.  It is 
formed by a single layer of specialized, flattened cells.  
Sloughing off and apoptosis of these specialized cells in 
Fuchs’ endothelial corneal dystrophy is one of the major 
causes of corneal transplantation, with other causes 
being ocular surgery, inflammation, and trauma [24]. Due 
to the wide range of cellular responses controlled by Rho 
kinase signaling pathway, it is hypothesized that ROCK 
inhibitors could play a part in both increasing cell 
adhesion and proliferation in the corneal endothelium 
[25]. This would allow for the preservation of corneal 
endothelial cells and the slowing of apoptosis.  For this 
reason, the use of Rho kinase inhibitors may also help 
with acute corneal endothelial damage, that can 
potentially occur in cataract surgery [21]. Successful 
clinical trials have been performed to show the positive 
effects of Rho kinase inhibitors on the corneal 
endothelium [16, 21, 24]. 
Diabetic Retinopathy and Macular Edema 
Diabetic retinopathy is a generalized term for disorders 
of the retina caused by diabetes. In the early stages of 
non-proliferative retinopathy, hemorrhages and vascular 
abnormality occur via microaneurysms and 
hyperpermeability of capillaries [6]. Macular edema is a 
progressed retinopathy, in which capillary segment walls 
lose the ability to control their own permeability, 
allowing fluid to leak in near the macula, and resulting in 
vision loss [26]. The proposed pathogenesis of diabetic 
retinopathy is related to increased leukocyte adhesion, 
leading to endothelial damage [27]. It has been shown 
that ROCK pathways promote leukocyte adhesion to 
microvascular structures, through increased levels of 
activated Intercellular Adhesion Molecule-1 (ICAM-1) and 
expression of other downstream proteins [28, 29]. 
Therefore, increased levels of activity of the Rho pathway 
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are related to the pathogenesis of diabetic macular 
edema and diabetic retinopathy [27]. Treatment with 
ROCK inhibitor intravitreal injections would be able to 
reduce adhesion of leukocytes to microvascular 
structures, allowing for a decrease in effects of diabetic 
retinopathy and macular edema. 
METHODS 
A literature review was performed using various 
electronic databases, including PubMed, Science Direct, 
and Journal of Ophthalmology. The dates used to define 
the search were between January 2010 and August, 
2018. For the PubMed search, Medical Subject Headings 
(MeSH) were used. The principal term used to dictate the 
MeSH search was “Rho kinase inhibitor”. It was 
connected to the following terms using the “AND” 
function: “open angle glaucoma”, “intraocular pressure”, 
“diabetic retinopathy”, “corneal endothelium”, “history”, 
and various others.  The abstracts for each article were 
studied to ensure relevance and significance to the 
review. Multiple clinical studies were identified and 
reviewed for relevance. Sources from these studies were 
identified, reviewed, and included as needed. Additional 
searches were made to find relevant literature through 
MeSH, using pertinent terms on the topic. All articles 
deemed relevant were included in this review. 
REVIEW OF THE LITERATURE  
Effects as an IOP-lowering Agent 
The use of ROCK inhibitors as IOP-lowering agents has 
been well-tested over the recent years.  Many studies 
have been performed to determine the optimal formula 
and dosage. This review focused on the use of ripasudil, 
K-115, and netarsudil, AR-13503, due to recent approval 
of these two drugs for ophthalmological use in therapy of 
glaucoma in Japan and the United States, respectively 
[18, 30]. 
Formula 
Ripasudil 
Ripasudil, also known as K-115 from various clinical trials, 
is an ophthalmic solution used as a treatment of 
glaucoma. It has the chemical formula of C15H18FN3O2S 
and has the International Union of Pure and Applied 
Chemistry (IUPAC), name being 4-fluoro-5-(((2S)-2-
methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline [31]. 
This new drug was shown to lower IOP within two hours 
of instillation of the drop solution, and was proven to do 
so consistently over a period of a full year [3, 32, 33]. 
However, this formula has also caused conjunctival 
hyperemia in the majority of subjects in each clinical trial 
reviewed.
26
  This ROCK-inhibiting drug gained approval in 
Japan, during year 2014 [10].
 
Side Effects of Ripasudil 
The most commonly seen adverse effect of Ripasudil is 
conjunctival hyperemia. This is a dose-dependent side 
effect and is seen in the majority of patients treated with 
Ripasudil. Conjunctival hemorrhage was also seen in 
treated patients, however, this side effect showed no 
dose dependency [32]. 
Netarsudil 
Netarsudil, known as AR-13503 in clinical trials, is a ROCK 
inhibitor with norepinephrine transport inhibitory 
activity, which helps lower the production of AH.  It has 
the chemical formula of C28H27N3O3 and has the IUPAC 
name of (4-((1S)-1-(Aminomethyl)-2-(isoquinolin-6-
ylamino)-2-oxoethyl)pheny)methyl2,4-dimethylbenzoate 
[34]. 
Netarsudil has been shown to decrease IOP within two 
hours of instillation and also to sustain this decrease for a 
24-hour period after dosing [19]. Netarsudil uses two 
mechanisms to lower IOP: By acting as both a ROCK 
inhibitor and a norepinephrine transport inhibitor. The 
latter helps to prolong reduction in IOP by constriction of 
vascular structures in the eye. This reduces blood flow to 
the ciliary processes, inhibiting production of AH [30]. 
Netarsudil is the main component of the drug Rhopressa, 
which gained US-FDA approval in December 2017 [35].
 
Side Effects of Netarsudil 
The most commonly seen side effect of using a netarsudil 
topical solution is conjunctival hyperemia. This was seen 
in more than half of the patients in clinical trial settings.  
A much smaller portion (approximately 20%) reported 
corneal verticillata, instillation site pain, and conjunctival 
hemorrhages. 
Mechanism 
Rho kinase inhibitors help lower IOP by increasing AH 
outflow, reducing AH production, and decreasing 
episcleral venous pressure (EVP) [36]. This is done in two 
different ways, which involves Rho kinase pathway 
inhibition and, as with Netarsudil, norepinephrine 
transport inhibition.  The relationships of these variables 
with IOP are shown in the modified Goldman equation, 
which is IOP is equal to EVP added to one divided by 
facility of outflow (C), multiplied by the difference of 
formation rate of AH (F) and resorption rate of AH (U).  In 
an equation form, this is: IOP = EVP + 1/C (F-U) [37]. 
Rho Kinase Pathway Inhibition 
As previously mentioned, the metabolic pathway of Rho 
kinase controls many aspects of cell morphology. When 
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inhibited, a change of cell shape and actin cytoskeleton 
structure occurs. After blocking the Rho kinase pathway, 
it has been observed that cell bodies become rounded 
and there is disruption of actin production [7, 8]. These 
two changes allow for greater outflow of AH through the 
trabecular meshwork, which ultimately results in a 
decrease of IOP. 
Norepinephrine Transport Inhibition 
Many ROCK-inhibiting drugs chemically include a 
norepinephrine transport inhibitor. This norepinephrine 
transport inhibitor helps reduce AH production and 
decreases EVP, which according to the modified Goldman 
equation, have a direct relationship with IOP [37, 38]. 
Norepinephrine transport inhibition lowers AH 
production by vasoconstriction, reducing blood flow to 
ciliary processes. A study showed that AH production 
may be reduced by 20% to 23% by the norepinephrine 
transport inhibitor [38]. This inhibitor affects the EVP via 
vasoconstriction, similar to the way brimonidine, a well-
known vasoconstrictor, has been shown to lower EVP in 
animals [39]. The reduction in EVP accounts for more 
than a third of the reduction in IOP, as shown in a study 
using Dutch Belted rabbits [40]. 
Dosage 
Ripasudil 
A phase II clinical trial was conducted during year 2013, 
in Japan, that determined the optimal dosage of 
ripasudil, K-115.  A group of individuals with open angle 
glaucoma were assigned to four different groups: a 
placebo, 0.1% ripasudil, 0.2% ripasudil, and 0.4% 
ripasudil. 
The results of this study showed that over an eight-week 
period, there was a decrease in baseline IOP in all groups 
using ripasudil. It also showed that as concentration of 
dosage increased, IOP decreased.  After comparing the 
results of the trial, researchers concluded that the 
optimal dosage, based on dose-response alone, was the 
0.4% dose, which had a reduction in baseline IOP of -4.5 
mm Hg, two hours after the last instillation of the drop. 
However, this study also showed that there may be a 
direct correlation between increased dosage and 
increased cases of conjunctival hyperemia.  The reported 
cases of conjunctival hyperemia were 13.0%, 43.4%, 
57.4%, and 65.3% in the placebo, 0.1% ripasudil, 0.2% 
ripasudil, and 0.4% ripasudil groups, respectively [32]. In 
Japan, a ripasudil drop solution was approved at a 0.4% 
concentration, as a twice daily treatment, to be used to 
treat glaucoma [18]. 
 
 
Netarsudil 
Netarsudil, the active compound in Rhopressa, has been 
tested in various clinical trials to prove a dose-dependent 
IOP-lowering effect.  In a study performed on Dutch 
Belted rabbits, the dose amounts of 0.005%, 0.01%, 
0.02%, and 0.04% were tested, while the same study 
tested 0.01%, 0.02%, and 0.04% on Formosan Rock 
monkeys. Day three measurements of the current study 
had the greatest reduction from baseline IOP.  The 0.04-
% dose yielded the greatest lowering of IOP in rabbits 
and monkeys, showing a reduction of IOP of -8.1±0.7 
mmHg and -7.5±1.1 mmHg, respectively.  All solutions 
produced trace amounts of mild hyperemia in the rabbits 
and monkeys, yet this was the only adverse effect noted. 
The IOP-lowering effect lasted longer in the monkeys 
than in the rabbits [30]. 
Another study using ten humans as subjects showed the 
results of using a 0.02% solution over an eight-day 
period.  Each subject received a drop of 0.02% Netarsudil 
solution, once a day, in one eye and a drop of the 
placebo in the other eye.  The results of this study 
showed that this 0.02% solution lowered IOP from 
baseline by -4.6±1.8 mmHg during this eight-day period.  
There was a greater reduction of 3.5 to 3.6 mmHg in the 
netarsudil eyes than in the placebo eyes. Each subject 
reported mild (and in one case moderate) conjunctival 
hyperemia [37]. 
The Rho Kinase Elevated IOP Treatment trials 1 and 2 
(ROCKET-1 and ROCKET-2), two phase three clinical trials, 
investigated safety and effectiveness relating to 
netarsudil and timolol in a sample of patients with 
elevated IOP. In a double-masked, randomized non-
inferiority clinical trial, Netarsudil once a day (q.d.), 
produced significant lowering from baseline IOP, which 
was non-inferior to timolol (ROCKET-1). Netarsudil twice 
a day (b.i.d.) showed non-inferiority to timolol as well 
(ROCKET-2) [41]. In the United States, a netarsudil drop 
was approved in a 0.02% concentration, as a one drop 
q.d. treatment to lower IOP for treatment of glaucoma 
[35]. 
Effects on the Healing of Corneal Endothelium 
Rho kinase inhibitors have been tested for use on the 
corneal endothelium.  They allowed for increased 
proliferation and decreased rate of apoptosis [16]. In 
general, the corneal endothelium has a very limited 
proliferation capacity.  Therefore, any structural damage 
is repaired by the migration of remaining corneal 
endothelium cells to the afflicted area, with a resulting 
drop in endothelium density [21]. There have been two 
proposed methods of delivery of ROCK inhibitors to heal 
the corneal endothelium, including topical eye drops and 
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an anterior chamber injection with cultured endothelial 
cells [42]. 
Mechanism 
 
 
Figure 3: A simplified View of the Hypothesized Treatment of Corneal Endothelial Damage using Anterior Chamber Injections and/or Topical Eye Drops 
of Rho Kinase Inhibitors. 
Cell Division 
Cells in the corneal endothelium are frozen in the cell 
cycle.  They cannot divide due to inhibiting factors in 
their surroundings and the tightly packed pattern of the 
corneal endothelium.  Furthermore, ROCK inhibitors, 
when used to treat corneal endothelial cells, allow for 
increased cyclin D levels and suppression of the 
phosphorylation of cyclin-dependent kinase inhibitor 1B, 
p27/kip1, which are regulators of cell division in corneal 
endothelial cells.  This allows for an increased rate of 
proliferation, as seen in Figure 3 above [21, 43]. 
Slowing of Cellular Apoptosis  
ROCK is directly related to apoptosis due to the cellular 
responses associated with its pathway. The actin 
cytoskeleton contractile force, regulated by the Rho 
kinase, allows for cellular contraction, membrane 
blebbing, and nuclear disintegration. Apoptosis in the 
corneal endothelium can be inhibited using ROCK 
inhibitors, which stop this contractile force from killing 
the cells. It has been shown that apoptosis can be slowed 
within a day of using Rho kinase inhibitors [44]. This 
mechanism is indicated in Figure 3. 
Increased Cell Adhesion 
Cellular adhesion is a key component in the healing of 
the corneal endothelium.  One method of healing the 
corneal endothelium is an anterior chamber injection of 
cultured endothelial cells and a Rho kinase inhibitor.  
Cellular adhesion allows for successful propagation of 
these cells to the interior layer of the cornea, as seen in 
Figure 3. Furthermore, ROCK inhibitors allow for 
increased cellular adhesion due to the enhancement of 
acto-myosin contractility [43]. Therefore, there is a 
greater potential for healing of corneal endothelial 
trauma using injection of cultured endothelial cells and 
Rho kinase inhibitors. 
Fuchs’ Corneal Dystrophy 
Fuchs’ endothelial corneal dystrophy is a progressive 
disease resulting in corneal endothelial cell loss. Cell 
death is one of the major contributing factors to the 
progression of this disease, affecting all layers of the 
cornea [42]. The current mainstay method of treatment 
for Fuchs is corneal transplant, however, recent studies 
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have investigated various alternative treatment options, 
including the use of ROCK inhibitors. 
The first treatment option is the use of a drop solution to 
help with the early stages of Fuchs’ corneal dystrophy 
and has been shown to slow cell apoptosis and increase 
cell proliferation [21]. These drops may also help in the 
treatment of late-onset Fuchs’ corneal dystrophy.  One 
successful case was reported during year 2013 in Japan, 
where a male patient with late-onset Fuchs’ corneal 
dystrophy was treated with a ROCK inhibitor for one 
week. Two weeks after the treatment, corneal 
transparency had returned and vision had improved from 
20/63 to 20/20. Another treatment option is the use of 
Rho kinase inhibitors as an injection with cultured 
corneal endothelial cells.  This procedure consists of 
injecting a combination of cultured corneal endothelial 
cells and a ROCK inhibitor in the anterior chamber of the 
eye and then allowing the patient to lie face-down to 
allow the cells to be directed towards the corneal 
endothelium.  The ROCK inhibitor facilitates increased 
adhesion of the cultured cells to the substrate, leading to 
an increase in corneal endothelial regeneration and 
restoration of corneal transparency [21]. This technique 
has been tested on rabbits and cynomolgus monkeys. 
The procedure enhanced the acceptance of these cells 
without any sign of harmful effects, such as secondary 
glaucoma, rejection, or problematic ectopic cell 
displacement [45]. 
Acute Corneal Trauma 
Acute corneal trauma, which occurs during cataract 
surgeries, can lead to corneal degeneration. The risk for 
corneal degeneration increases with decreasing density 
of corneal endothelial cells [21]. ROCK inhibitors can be 
used to increase the proliferation rates of these cells in 
order to allow for greater density in this layer. This allows 
for increased healing and migration of corneal 
endothelial cells to cover the afflicted area. 
In Japan, three patients, who had undergone cataract 
surgery, developed severe corneal edema and corneal 
haziness, and were at high risk for subsequent 
decompensation. Due to these conditions, they were all 
treated with a Rho kinase inhibitor drop.  Within one to 
two months, there was recovery of corneal transparency, 
showing an increase in corneal endothelial cell density in 
all three patients [21]. 
Effects on Diabetic Retinopathy 
The Rho pathway is involved in the pathogenesis of 
diabetic retinopathy, through the promotion of leukocyte 
adhesion to diabetic retinal microvascular structures 
[46]. The adhesion of leukocytes to vascular endothelium 
enables the release of inflammatory cytokines, growth 
factors, and vascular permeability factors, which 
ultimately compromise the blood-retinal barrier [47]. 
Activation of the Rho kinase pathway also has a direct 
correlation with microvascular endothelial damage via 
inactivation of the nitric oxide synthase.  Inhibition of 
nitric oxide levels prevents vasodilation and allows for 
apoptosis, which increases the leukocyte-induced 
damage [27]. 
A Rho kinase inhibitor was tested on diabetic rats and 
was shown to decrease retinal leukocyte adhesion and to 
slow the corneal endothelium damage that had been 
caused by prior adhesion of leukocytes.
28
 In this same 
experiment, nitric oxide synthase production was 
inhibited with L-NG-Nitroarginine methyl ester, L-NAME, 
a well-known inhibitor of nitric oxide synthases. When 
this was achieved, the positive effects of the Rho kinase 
inhibitor were sufficiently blocked [27, 28]. It is necessary 
for there to be nitric oxide production in order for the 
Rho kinase inhibitor effects to be suffice on 
microvascular endothelial cells. This shows that a Rho 
kinase inhibitor treatment can be beneficial for patients 
with symptoms of diabetic retinopathy, by reducing the 
adhesion of leukocytes and increasing nitric oxide levels 
[28]. 
Mechanism 
Prevention of Creation of Anchor Sites 
Rho kinase inhibitors work to treat diabetic retinopathy 
by decreasing the adhesion of leukocytes and by slowing 
leukocyte-induced damage.  Used as an intravitreal 
injection, the Rho kinase inhibitor slows the synthesis of 
various downstream proteins in the Rho pathway as well 
as ICAM-1. These proteins, such as ezrin and radixin, 
when clustered with ICAM-1, are the anchor sites for 
leukocytes [27, 29]. Furthermore, ROCK inhibitors stop 
the creation of these anchor sites, which stops further 
damage to the endothelium. This is indicated in Figure 4. 
A study from Kyushu University of Japan examined the 
effects of Rho kinase inhibitors related to the symptoms 
of diabetic retinopathy.  One measured outcome was 
leukocyte adhesion in artificially diabetes-induced rats.  
After being treated with fasudil, a Rho kinase inhibitor, 
the rats showed a suppression of leukocyte adhesion by 
68% [28]. The ROCK pathway may also contribute to 
damage to Müller cells induced by hypoxia and oxidative 
stress. Moreover, the ROCK inhibitor Y-27632 
demonstrated protection of mouse retinal Müller cells 
against cellular injury caused by oxidative stress and 
hypoxia [48]. 
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Figure 4: A simplified View of the Mechanism of Rho Kinase (ROCK) Inhibitor Treatment for Diabetic Retinopathy 
 
Slowing of Microvascular Endothelial Damage 
The ROCK inhibitors also help slow down endothelial 
damage in the retinal microvascular vessels.  They do this 
by reversing the endothelial nitric oxide synthase 
inactivation caused by the Rho pathway.  This synthase 
creates nitric oxide, a potent vasodilator and anti-
apoptotic factor [27]. Nitric oxide helps protect cells 
within microvascular structures without causing 
increased adhesion of leukocytes, which would cause 
further damage [27]. This permits blood flow to be 
restored to the cells surrounding the macula without risk 
of increased vessel permeability.  The restoration of nitric 
oxide is fundamental in reducing damage caused by 
leukocyte adhesion to microvascular endothelial cells in 
the retina and for reducing apoptosis in these cells [49]. 
In the same investigation from Kyushu University of 
Japan, diabetes-induced rats, treated with Rho kinase 
inhibitors, showed deregulation of the nitric oxide 
synthase by 35% [28]. This means that the inhibition of 
the Rho pathway allowed for an increase of nitric oxide 
production.  In this experiment, nitric oxide was also 
shown to be an integral part of the protection of 
endothelial cells in the retina. Furthermore, L-NAME was 
used to block the production of nitric oxide in these rats 
and, by doing so, significantly reversed the protective 
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effect the Rho kinase inhibitor had on apoptosis in the 
endothelial cells [28]. 
Treatment Method 
The proposed methodology of treatment for diabetic 
retinopathy is by an intravitreal injection of Rho kinase 
inhibitors. These injections will need to be frequently 
administered due to the short half-life of the compound 
in the vitreous chamber [27]. Another proposed method 
of administration is intravitreal implantation. This device 
would deliver Rho kinase inhibitors over time in order to 
maximize the desired effects [27]. This implantation 
would lessen the frequency of visits and injections for 
users, as proven by previous intravitreal implantations, 
such as Iluvien [26]. For optimal results, it is preferable to 
place the implantation when early symptoms of diabetic 
retinopathy occur, such as when microaneurysms 
appear. This would help slow the progression of retinal 
microvascular damage and maintain visual acuity [27]. 
Other Uses Being Investigated 
Rock inhibitors have been investigated for the role that 
Rho kinase plays in the myopia scleral remodeling 
pathway [50]. 
CONCLUSIONS 
The use of Rho kinase inhibitors in ophthalmology has 
been studied for many different treatments.  Its use has 
been proven to be of benefit in the treatment of 
glaucoma, the healing of corneal endothelium, and in 
progressive forms of diabetic retinopathy. Although 
there is evidence showing that use of Rho kinase 
inhibitors is related to increase in conjunctival 
hyperemia, the use of this new therapy can be pivotal in 
the treatment of ophthalmology patients around the 
world. More clinical trials investigating the reviewed 
treatment options of Rho kinase inhibitors are necessary 
to further validate previous findings on the topic. 
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